Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is -624817.90% as of the fiscal period ended Saturday, December 31, 2016.
Limited history available
IMUX EBITDA Margin has fewer than three reported periods, so a trend chart would be misleading.
EBITDA MARGIN
-624817.90%
EBITDA MARGIN AVG TTM
N/A
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$108.30M
EBITDA Margin
28.85%
TTM Avg
28.85%
3Y Avg
28.85%
5Y Avg
28.85%
Market Cap
$108.76M
EBITDA Margin
-4735.97%
TTM Avg
-4735.97%
3Y Avg
-4735.97%
5Y Avg
-4735.97%
Market Cap
$107.43M
EBITDA Margin
5.60%
TTM Avg
2.28%
3Y Avg
0.00%
5Y Avg
-2.15%
Market Cap
$107.28M
EBITDA Margin
-6164.17%
TTM Avg
-4620.17%
3Y Avg
-2654.54%
5Y Avg
-2163.85%
Market Cap
$109.07M
EBITDA Margin
-10.96%
TTM Avg
-24.45%
3Y Avg
-32.87%
5Y Avg
-38.11%
Market Cap
$109.14M
EBITDA Margin
-699.90%
TTM Avg
-1930.94%
3Y Avg
-1689.05%
5Y Avg
-1903.35%
Market Cap
$110.19M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$105.67M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Immunic, Inc. (IMUX) | $108.15M | -624817.90% | N/A | N/A | N/A |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $108.30M | 28.85% | 28.85% | 28.85% | 28.85% |
| Outlook Therapeutics, Inc. (OTLK)vs › | $108.76M | -4735.97% | -4735.97% | -4735.97% | -4735.97% |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $107.43M | 5.60% | 2.28% | 0.00% | -2.15% |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $107.28M | -6164.17% | -4620.17% | -2654.54% | -2163.85% |
| Apyx Medical Corporation (APYX)vs › | $109.07M | -10.96% | -24.45% | -32.87% | -38.11% |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $109.14M | -699.90% | -1930.94% | -1689.05% | -1903.35% |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $110.19M | N/A | N/A | N/A | N/A |
| Polaryx Therapeutics, Inc. Common Stock (PLYX)vs › | $105.67M | N/A | N/A | N/A | N/A |
| Definitive Healthcare Corp. (DH)vs › | $105.01M | 6.31% | -127.53% | -89.97% | -50.55% |
Gross Margin
0.0%
EBITDA Margin
-624817.9%
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2016-12-31 | -624817.90% |
